| Bioactivity | SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic glucose output. SRI-37330 can be used in the research of obesity and diabetes[1]. |
| Target | TXNIP |
| Invitro | SRI-37330 (1 μM, 24 h) inhibits the activity of the human TXNIP promoter in INS-1 cells[1].SRI-37330 (1 μM, 24 h) inhibits Mrna and protein levels of TXNIP in INS-1 cells[1].SRI-37330 (5 μM, 24 h) inhibits polymerase II (Pol II) binding to the E-box motif region of the TXNIP promoter[1].SRI-37330 (5 μM, 24 h) lowers glucagon secretion in TC1-6 cells[1].SRI-37330 (0-5 μM, 24 h) inhibits glucagon-induced glucose output from primary hepatocytes[1]. RT-PCR[1] Cell Line: |
| In Vivo | SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) decreases glucagon secretion and action and blocks hepatic glucose output[1].SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) is well tolerated in male C57BL/6J mice[1].SRI-37330 (100 mg/kg, p.o., in drinking water, 3 weeks) reverses obesity- and STZ-induced diabetes and hepatic steatosis in mice[1]. Animal Model: |
| Name | SRI-37330 |
| CAS | 2322245-42-9 |
| Formula | C16H19F3N4O2S |
| Molar Mass | 388.41 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen) |
| Reference | [1]. Thielen LA, et al. Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action. Cell Metab. 2020 Sep 1;32(3):353-365.e8. |
SRI-37330
CAS: 2322245-42-9 F: C16H19F3N4O2S W: 388.41
SRI-37330 is an orally active TXNIP inhibitor. SRI-37330 decreases glucagon secretion and action and blocks hepatic gluc
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.